Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000001800
$102.51
+1.99% · live
Updated
$177.79B market value
From ABBOTT LABORATORIES's FY2025 10-K, filed Feb 20, 2026 · read the filing
ABBOTT LABORATORIES develops and makes medicines. It took in $44.33B last year, which makes it a large company. Of every dollar it sells, about 15 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by MCCOY JOHN A. JR., not under a pre-arranged plan.
$3.0K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From ABBOTT LABORATORIES's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$13.40B → $6.52B
Profit margin
31.9% → 14.7%
Earnings per share
$7.72 → $3.76
Operating income
$6.83B → $8.05B
Measured against FY2024, from the 10-K filed Feb 20, 2026
Deteriorated: -51.3%
$13.40B to $6.52BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
ABT rose 1.99% on the latest quote. The average Health Care company tracked here moved +1.61%, and the S&P 500 −1.04%. That is in line with its sector and 3.0 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 8% a year for the next 10 years. Over the last 10 years it grew by about 15% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 15 cents of every dollar of sales as profit, earning $6.52B last year.
Slowly. Sales grew 5.7% last year.
No. Its borrowings would take under a year of cash flow to clear. For every $1 it owes, it owns $2.51 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 63 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 43% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $6.52B and generated $9.57B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 20, 2026Filing for FY2025 | FY202410-K · Feb 21, 2025Filing for FY2024 | FY202310-K · Feb 16, 2024Filing for FY2023 | FY202210-K · Feb 17, 2023Filing for FY2022 | FY202110-K · Feb 18, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | +5.7% |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B | +3.3% |
| Gross profit | $25.01B† | $23.24B† | $22.13B† | $24.51B† | $24.54B† | +7.6% |
| Gross marginGross profit ÷ revenueWhat is this? | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% | +1.0 pts |
| Selling, general and administrative | $12.33B | $11.70B | $10.95B | $11.25B | $11.32B | +5.4% |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | +18.0% |
| Operating marginOperating income ÷ revenueWhat is this? | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% | +1.9 pts |
| Interest expense | $493.0M | $559.0M | $637.0M | $558.0M | $533.0M | −11.8% |
| Income before tax | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B | +20.7% |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | −51.3% |
| Net marginNet income ÷ revenueWhat is this? | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | −17.2 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $3.76 | $7.72 | $3.29 | $3.93 | $3.99 | −51.3% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| ABTABBOTT LABORATORIES · this page | 9.0/10 | 6/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Had shares withheld to cover taxes — 52,507 shares at $103.99 ($5.5M)
Holds 81,230 shares after this filing.
Had shares withheld to cover taxes — 388 shares at $110.36 ($42.8K)
Holds 70,784 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Reported another event
Read the filingPublished results
Read the filingWrite down why you are following ABBOTT LABORATORIES, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device
Yahoo ·
GE HealthCare Technologies (GEHC) vs. DHR and MDT: Can a $23.9B Backlog and AI Innovation Drive a Healthcare Re-Rating?
Yahoo ·
Abbott (ABT) Stock Shrugs Off Q3 Results As Spin Off Looms
Yahoo ·
Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says
Yahoo ·
Australia Bionic Devices Market Size, Share, Growth, and Forecast 2026-2034 Featuring Profiles of Cochlear, Medtronic Australasia, Edwards Lifesciences Australia, Baxter Int'l, Boston Scientific Corp., Abiomed Australia, Abbott Labs
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from ABT's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 20, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 6/9 | 10-K, filed Feb 20, 2026 |
| FY2024 | 8.0 | 7/9 | 10-K, filed Feb 21, 2025 |
| FY2023 | 8.0 | 6/9 | 10-K, filed Feb 16, 2024 |
| FY2022 | 9.0 | 6/9 | 10-K, filed Feb 17, 2023 |
| FY2021 | 10.0 | 9/9 | 10-K, filed Feb 18, 2022 |
| FY2020 | 9.0 | 7/9 | 10-K, filed Feb 19, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
4.84
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.51
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −17.2 pts
31.9% to 14.7%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -51.3%
$7.72 to $3.76Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +18.0%
$6.83B to $8.05BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +16.4%
$6.35B to $7.39BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: -21.6%
$12.63B to $9.90BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +5.7%
$41.95B to $44.33BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +7.6%
$23.24B to $25.01BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +1.0 pts
55.4% to 56.4%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +1.9 pts
16.3% to 18.2%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +11.9%
$7.62B to $8.52BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +7.3%
$3.84B to $4.12BNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Q1 FY2026 against Q1 FY2025, from the 10-Q filed Apr 29, 2026 — read it.
Deteriorated: +132.7%
$12.74B to $29.64BCritical
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -20.6%
$1.69B to $1.34BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -18.7%
$1.32B to $1.08BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −4.3 pts
16.3% to 12.0%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −3.1 pts
12.8% to 9.6%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -18.8%
$0.76 to $0.62Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Changed: -17.6%
$484.0M to $399.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +7.8%
$10.36B to $11.16BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +6.5%
$5.89B to $6.27BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Changed: +7.0%
$1.03B to $1.10BNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 6% and 11%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 32 analysts covering this company, as of . Their views, not this site's.
Of 32 analysts publishing on this company, 12 say strong buy, 14 say buy and 6 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 0.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 30.5x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 5.7% |
| 14.7% |
| 27.25x |
| 0.66x |
| ISRGINTUITIVE SURGICAL INC | 10.0/10 | 7/8 | 20.5% | 28.4% | 55.19x | 0.14x |
|---|
| SYKSTRYKER CORP | 9.0/10 | 6/9 | 11.2% | 12.9% | 36.10x | 1.13x |
|---|
| BSXBOSTON SCIENTIFIC CORP | 10.0/10 | 8/9 | 19.9% | 14.4% | 23.48x | 0.80x |
|---|
| BDXBECTON DICKINSON & CO | 7.0/10 | 6/9 | 8.2% | 7.7% | 34.09x | 1.18x |
|---|
| EWEdwards Lifesciences Corp | 9.0/10 | 6/9 | 11.5% | 17.7% | 48.73x | 0.32x |
|---|
| IDXXIDEXX LABORATORIES INC /DE | 9.0/10 | 8/9 | 10.4% | 24.6% | 42.64x | 1.09x |
|---|
| RMDRESMED INC | 9.0/10 | 8/9 | 9.9% | 26.9% | 23.96x | 0.36x |
|---|
| Median of peers | 9.0/10 | — | 11.2% | 17.7% | 36.10x | 0.80x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Had shares withheld to cover taxes — 52 shares at $110.36 ($5.7K)
Holds 24,576 shares after this filing.
Sold on the open market — 27 shares at $109.54 ($3.0K)
Holds 24,549 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 27 shares ($3.0K) on or after .
Shares originally obtained via Restricted Stock Award Vested.
Filed notice to sell 398,832 shares ($46.2M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 5,850 shares ($642.5K) on or after .
Shares originally obtained via Restricted Stock Award Vested.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Made a Regulation FD disclosure · Reported another event
Quarterly report on Form 10-Q
Read the filingPublished results
Read the filingQuarterly report for Q1 FY2026
Revenue +7.8% · Operating margin −4.3 pts · Long-term debt +132.7% — against Q1 FY2025
Read the filingHad a director or senior officer leave or join · Amended its charter or changed its financial year · Held a shareholder vote
Read the filingReported another event
Read the filingPublished results
Read the filingReported another event
Read the filingProxy statement for a shareholder meeting
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingSigned a material agreement
Read the filingAmended its charter or changed its financial year
Read the filingAnnual report for FY2025
Revenue +5.7% · Operating margin +1.9 pts · Profit -51.3% — against FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Amended its charter or changed its financial year
Read the filingSuspended trading in its employee benefit plans
Read the filingSigned a material agreement · Made a Regulation FD disclosure · Reported another event
Read the filingQuarterly report for Q3 FY2025
Revenue +6.9% · Profit margin −1.0 pts · Gross profit +6.0% — against Q3 FY2024
Read the filingYahoo ·
Primary sources and further research